Alessandro Pancrazzi, Francesco Bloise, Alice Moncada, Roberta Perticucci, Stefania Vecchietti, Francesca Pompili, Francesca Ricciarini, Silvia Lenzi, Cristina Gatteschi, Sabrina Giusti, Maria Pia Rosito, Sabrina Del Buono, Paola Belardi, Alessandra Bruni, Filippo Borri, Andrea Campione, Lorella Laurini, Rossella Occhini, Loretta Presenti, Viviana Viticchi, Maja Rossi, Sara Bardi, Antonio D'Urso, Simona Dei, Duccio Venezia, Raffaele Scala, Carmelo Bengala, Nicola Libertà Decarli, Andrea Carnevali, Carlo Milandri, Agostino Ognibene
Background Liquid biopsy is mainly used to identify tumor cells in pulmonary neoplasms. It is more often used in research than in clinical practice. The BL-MOL-AR study aims to investigate the efficacy of next-generation sequencing (NGS) and clinical interpretation of the circulating free DNA (cfDNA) levels. This study reports the preliminary results from the first samples analyzed from patients affected by various neoplasms: lung, intestinal, mammary, gastric, biliary, and cutaneous. Methods The Biopsia Liquida-Molecolare-Arezzo study aims to enroll cancer patients affected by various malignancies, including pulmonary, intestinal, advanced urothelial, biliary, breast, cutaneous, and gastric malignancies...
September 2023: Global medical genetics